Brief: Bionomics Says Decided To Proceed With Evaluating Its BNC210 For Acute Treatment Of Social Anxiety Disorder
20/09/2021 02:52
Sept 20 (Reuters) - Bionomics Ltd BNO.AX :
* DECIDED TO PROCEED WITH EVALUATING ITS BNC210 FOR ACUTE
TREATMENT OF SOCIAL ANXIETY DISORDER
* PLANNED COMMENCEMENT OF A CLINICAL TRIAL OF BNC210 BY
2021-END
Source text for Eikon: ID:nASX2pP230
Further company coverage: BNO.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bionomics
See all newsBrief: Bionomics Announces Intention To Delist From The Australian Securities Exchange (ASX)
Brief: Bionomics Announces Its Intention To De-List From Australian Securities Exchange
Australia's Bionomics plunges to record low after co announces ASX delisting
Brief: Bionomics Ltd Seeks Trading Halt
Brief: Bionomics Says Alan Fisher Appointed Chair Of Board Of Directors